ViroLogik is a biopharmaceutical company which is developing innovative drugs for treatment of viral diseases. The focus is on Hepatitis C (HCV). Second indication is HIV- (Human Immunodeficiency Virus, AIDS) infections. ViroLogik is following a novel strategy to prevent formation of drug resistance.

ViroLogik has already obtained clinical proof of principle that proteasome inhibitors can effectively reduce the viral load in patients with HCV infection, which were refractory to classical HCV therapy.